Pay in 4 interest-free payments of $6.86 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Danuglipron (from Pfizer) showed mixed results and faced development challenges
[5] Kuo, CC., Chuang, MH., Li, CH
/assets/production/practices/3280152d22c7599df4208c7f13bd6f106ba2a939/images/2788239.jpeg)
Researchers using a national database of health care providers on the electronic medical record Epic found no evidence of excess risk of thyroid cancer
392 In prostate cancer group, the positive rate of BCL9 was 53.1% (52/98), whereas in benign group the positivity rate was 25.0% (5/20
Most secondary endpoints were not measured at screening, therefore several biochemical changes brought about by weight loss during run-in cannot be evaluated
Li, Weiwei
US$ 25.50
US$ 20.12
US$ 24.37
US$ 29.56
US$ 29.78
US$ 20.81
US$ 27.51
